Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 7/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27351610 | 0.94 | CRBN (0.51) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL26740495 | 0.94 | CRBN (0.51) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL31438897 | 0.94 | CRBN (0.51) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL27351609 | 0.94 | CRBN (0.51) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL30767695 | 0.94 | CRBN (0.51) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL26740461 | 0.90 | CRBN (0.53) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL26740467 | 0.90 | CRBN (0.53) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL26740615 | 0.90 | CRBN (0.49) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL29739487 | 0.90 | CRBN (0.49) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL26740509 | 0.89 | CRBN (0.53) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CRBN 113/4885CSNK1A1 167/4885IKZF2 254/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CRBN 107/4885CSNK1A1 164/4885IKZF2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.